Latest Farnesoid X receptor Stories
A new study presented today at the International Liver Congress™ 2012 demonstrates that the gut microbiota has a profound systemic effect on bile acid metabolism.
NEW YORK, March 29, 2011 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis (NASH), which will evaluate Intercept's first-in-class farnesoid X receptor (FXR) agonist obeticholic acid (OCA) as a novel therapy for NASH.
Researchers at UT Southwestern Medical Center have discovered a hormone pathway that potentially could lead to new ways of treating type 1 diabetes independent of insulin, long thought to be the sole regulator of carbohydrates in the liver.
NEW YORK, Jan.
NEW YORK, Oct.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.